| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tetrapentylammonium bromide does not have a defined pharmacological target. It is a quaternary ammonium salt used primarily as a phase transfer catalyst in organic synthesis. The compound facilitates the transfer of reactants between immiscible phases, enabling reactions that involve ionic species. It is also used as an electrolyte in electrochemical applications.
|
|---|---|
| ln Vitro |
In study pertaining to life sciences, tetrapentylammonium bromide is a biochemical reagent that can be utilized as an organic substance or biological material.
In vitro, Tetrapentylammonium bromide is used as a phase transfer catalyst in organic synthesis reactions to facilitate the transfer of reactants between immiscible phases. It can facilitate reactions that involve ionic species by aiding the transfer of ions between different phases, such as aqueous and organic solvents. The compound is also used as an electrolyte in electrochemical applications and as a structure-directing agent for the synthesis of zeolite-like frameworks. |
| ln Vivo |
In vivo data for Tetrapentylammonium bromide are not available, as the compound is a phase transfer catalyst and chemical reagent used for in vitro applications. It is not intended for in vivo administration and has no established in vivo pharmacokinetic or pharmacodynamic profile. The compound is not designed for therapeutic use.
|
| Enzyme Assay |
For in vitro chemical reactions, Tetrapentylammonium bromide is used as a phase transfer catalyst. The compound is added to biphasic reaction mixtures (typically aqueous-organic) at catalytic amounts (1-10 mol%). It facilitates the transfer of ionic reactants or reagents from the aqueous phase to the organic phase, enabling reactions to proceed. The compound is also used as an electrolyte in electrochemical experiments.
|
| Cell Assay |
For in vitro cell-based experiments, Tetrapentylammonium bromide is not typically used directly in cell culture. It is a phase transfer catalyst and chemical reagent used for organic synthesis. The compound may be used in the synthesis of compounds that are subsequently tested in cell-based assays, but it is not added directly to cell cultures as a test compound.
|
| Animal Protocol |
In vivo animal studies for Tetrapentylammonium bromide are not applicable, as the compound is a phase transfer catalyst used for chemical synthesis. No animal studies have been conducted for this compound as a therapeutic agent, and it is not intended for diagnostic or therapeutic use in animals or humans.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Tetrapentylammonium bromide are not available, as the compound is not a drug and is not administered to living organisms. The compound is a quaternary ammonium salt with a molecular weight of approximately 378.47 g/mol. As a charged quaternary ammonium compound, it is expected to have very low oral bioavailability and poor membrane permeability.
|
| Toxicity/Toxicokinetics |
Tetrapentylammonium bromide is a research chemical and should be handled with appropriate laboratory safety precautions. As a quaternary ammonium salt, it may cause skin and eye irritation. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
Tetrapentylammonium bromide (CAS 866-97-7) is primarily a research-grade chemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as a phase transfer catalyst in organic synthesis, facilitating the transfer of reactants between immiscible phases. The compound is also used as an electrolyte in electrochemical applications and as a structure-directing agent for the synthesis of zeolite-like frameworks. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C20H44BRN
|
|---|---|
| Molecular Weight |
378.48
|
| Exact Mass |
377.265
|
| CAS # |
866-97-7
|
| Related CAS # |
15959-61-2 (Parent)
|
| PubChem CID |
70086
|
| Appearance |
White to yellow solid powder
|
| Density |
0.92333 g/cm3 (35.00℃)
|
| Melting Point |
100-101ºC(lit.)
|
| Index of Refraction |
1.5260 (estimate)
|
| LogP |
3.568
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
22
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC[N+](CCCCC)(CCCCC)CCCCC.[Br-]
|
| InChi Key |
SPALIFXDWQTXKS-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C20H44N.BrH/c1-5-9-13-17-21(18-14-10-6-2,19-15-11-7-3)20-16-12-8-4;/h5-20H2,1-4H3;1H/q+1;/p-1
|
| Chemical Name |
tetrapentylazanium;bromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (264.21 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6421 mL | 13.2107 mL | 26.4215 mL | |
| 5 mM | 0.5284 mL | 2.6421 mL | 5.2843 mL | |
| 10 mM | 0.2642 mL | 1.3211 mL | 2.6421 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
